Mangoceuticals, Inc.
MGRXHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Mangoceuticals, Inc. focuses on Health Information Services services and products. Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. At a $8.9M market cap, Mangoceuticals, Inc. ranks as a micro-cap company within healthcare. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
Market Cap
$8.9M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.99
EPS (Fwd)
—
ROE
-95.1%
ROA
-48.0%
Cash
$228,688
Total Debt
$279,207
Free CF
$1.4M
52W Change
-81.2%
Annual Financials
Cash vs Debt
Where MGRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MGRX finished 7.32% below its 150-day moving average ($0.41) and 29.63% below its 200-day moving average ($0.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MGRX overbought or oversold?
At the September 3, 2026 close, MGRX's RSI(14) was 24.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, MGRX has $229K in cash with $279K in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $1.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -95.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $9K to $456K.
Investors considering Mangoceuticals, Inc. should weigh the typical risks associated with MGRX's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Mangoceuticals, Inc. and its sector.